Mindfulness and Shared Decision Making

Sponsor
Methodist Health System (Other)
Overall Status
Recruiting
CT.gov ID
NCT04255082
Collaborator
(none)
40
1
39.6
1

Study Details

Study Description

Brief Summary

The purpose of this study is to assess the impact of mindfulness-based interventions on patient stress, patient-provider communication, and other measures of SDM at MDMC.

There is a need to have a quantifiable measure of perceived stress and communication ability in patients. This is the first study of its kind to be conducted at MDMC. This pilot study will not only benefit the patients but also contribute to the medical community's understanding of treating the whole patient through mindfulness and shared decision making.

2.1. Study Objectives 2.1.1. Primary Objective To assess the impact of mindfulness-based interventions on inpatients and outpatients stress, patient-provider communication, and other measures of SDM at MDMC.

2.1.2. Secondary Objectives To evaluate the feasibility of such a study in the patient population.

Condition or Disease Intervention/Treatment Phase
  • Other: assess the impact of mindfulness-based interventions on inpatients' and outpatients' stress, patient-provider communication, and other measures of SDM at MDMC.

Detailed Description

This will be a prospective cohort of patients at MDMC, The Liver Institute, and Texas Oncology between 6/1/2018 and 12/31/2020. Subject records will be reviewed to identify case-based details including demographics, diagnosis, and date of diagnosis. Subjects will complete survey instruments to assess their levels of stress and anxiety, and the impact of the same on their ability to communicate at baseline, after the stress management coaching session, following their treatment planning visit (outpatients only), and one week after the visit (by mail). Providers will also complete the dyadic OPTION instrument (for outpatients only) to empirically assess the perceived degree of patient involvement in the treatment planning process. The face-to-face stress management coaching session will occur approximately an hour before meeting with the treatment planning team for outpatients and at a designated time identified for inpatients. The session will focus on mindfulness-based interventions on stress regulation, communication, and shared decision making. A comprehensive evaluation will be performed and a unique treatment plan developed for each subject based on a biopsychosocial model to address the mind, body, and spirit. Nutritional counseling and lifestyle coaching will also be addressed.

2.2. Study Outcome Measures 2.2.1. Primary Outcome

The effectiveness of the mindfulness-based intervention which will be assessed by:

Baseline and post-intervention perception of stress and anxiety Impact of stress on communication Emotional-Brain state Level of SDM during a pivotal visit with provider e.g. treatment planning visit (for outpatients only) The Emotional Distress-Anxiety (PROMIS, 2016), Communication Short Form (Cella, PROMIS, 2013), Emotional/Brain State Question (Mellin, 2017) and The Shared Decision Making dyadic OPTION scale (Melbourne, 2016) will be used to evaluate these outcomes.

2.2.2. Secondary Outcome Feasibility of such a study in the patient population and setting. This will be measured by the barriers encountered and the ability to successfully carry out the study.

2.3 Study Enrollment: 2.3.1.Study Inclusion Criteria

  • Age 18 years or olde

  • Newly diagnosed cancer patient (breast, pancreatic, head & neck, hepatocellular carcinoma, cholangiocarcinoma, and colorectal carcinoma with metastases to the liver) at MDMC, the Liver Institute, or Texas Oncology

  • Provided written informed consent 2.3.2. Study Exclusion Criteria

  • Below 18 years of age

  • Does not have cancer

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
40 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Mindfulness and Shared Decision Making
Actual Study Start Date :
Aug 15, 2018
Anticipated Primary Completion Date :
Dec 1, 2021
Anticipated Study Completion Date :
Dec 1, 2021

Outcome Measures

Primary Outcome Measures

  1. Baseline and post-intervention perception of stress & anxiety by answering survey questions [6/1/2018 and 12/31/2020]

    Effectiveness of the mindfulness-based intervention which will be assessed by survey questions: Baseline and post-intervention perception of stress and anxiety t of stress on communication Emotional/Brain state Level of SDM during a pivotal visit with provider e.g. treatment planning visit (for outpatients only) The Emotional Distress-Anxiety (PROMIS, 2016).

Secondary Outcome Measures

  1. Feasibility of a study in the patient population and setting by any difficulties faced during the study phase [6/1/2018 and 12/31/2020]

    Feasibility of such a study in the patient population and setting. This will be measured by the barriers encountered and the ability to successfully carry out the study. The study questionnaire will be used for the subjects.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Age 18 years or older

  • Inpatients and outpatients receiving treatment at MDMC, the Liver Institute, or Texas Oncology

  • Provided written informed consent

Exclusion Criteria:
  • Below 18 years of age

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Liver Institute at Methodist Dallas Medical Center Irving Texas United States 75603

Sponsors and Collaborators

  • Methodist Health System

Investigators

  • Principal Investigator: Parvez Mantry, M.D., Methodist Health System

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Methodist Health System
ClinicalTrials.gov Identifier:
NCT04255082
Other Study ID Numbers:
  • 030.HEP.2018.D
First Posted:
Feb 5, 2020
Last Update Posted:
Jun 24, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 24, 2021